AMN Healthcare Services stock
AMNNYSEAMN Healthcare Services, Inc., HealthcareISIN US0017441017
65Score 65 out of 100, Neutral
Price and trend
62 / 100
Price history
+126% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 27% above it.
Since March 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Sharply down: the price has fallen very quickly lately (RSI 26).
The price is 24% below its 52-week high. Largest decline in 20 years: 88% (November 2022 to January 2026).
Chart figures for advanced users
- SMA 50$38.52
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$29.44
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)26
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$15.10
- The lowest closing price of the last twelve months.
- Resistance$49.00
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- AMN Healthcare Services, Inc. belongs to the Medical (Care Facilities) industry (United States) and, with a market value of $1.44B, is number 39 of 57 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $2.73B (down 8.5% year on year) and a loss of $95.7M.
- For fiscal 2026, analysts expect on average revenue of $3.36B (up 22.9%) and adjusted earnings per share of $3.29 (up 141.8%).
Show more
- MEQIRI Score 65 out of 100 (Neutral): rank 209 of 702 in Healthcare, median 53.
- The P/E is 13.8 (Medical (Care Facilities) median 19.6, own median of recent years 17.8).
- Our model puts fair value at $33.74, with the price 11% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings turn into cashFree cash flow 300% of earnings over the last 12 months.Fundamentals 80
- Share buybacksShare count down 19% since 2020.Capital allocation 71
- Modestly valuedP/E 13.8, Medical (Care Facilities) median 19.6, own median 17.8.Valuation 70
Weaknesses
- Margin fallingOperating margin 1.2%, average of the prior years 8.9% (to 2024).Profitability 51
- Analysts expect falling earningsDown 50.3% a year through 2028 (estimates from 5 analysts).Growth 64
- Turned to a lossEarnings per share from $1.49 in 2020 to −$2.48.Growth 64
Its standout strengths are momentum and fundamentals, while stability holds the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- price up very strongly over the past year
- high price swings
What lowers it
- solid fundamentals
Valuation
Valuation signal
Fairly valuedIn our model the price counts as cheap below $22.49 and expensive above $67.48 (uncertainty very high, based on the price swings of the past year).
The two parts of the fair value come to $14.17 (cash-flow model) and $53.31 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $32.86, at 7.8% it would be $35.03.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (19.6).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In fiscal 2025, revenue fell 8.5% on the prior year. Revenue has grown solidly since 2006, at about 5% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 28%, operating 1%, net −4%. Last 12 months: net 3%.
Debt & balance sheet
latest quarterDebt is moderate, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 18 Feb 2027in 97 days
- Last reported
- 5 Nov 2026EPS reported $1.16 (expected $0.23)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $3.290.0%
- Revenue
- $3.36B0.0%
- Earnings per share
- $0.940.0%
- Revenue
- $2.67B0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +9.8%Q2 revenue was 6% above the high end of guidance, but several one-time items will not recur in Q3, and the Q3 gross margin guide is a bit below Q2 on a normalized basis.
“Excluding these items, our Q2 revenue would still be almost 2% above the high end of our guidance range, and our EBITDA margin would be at the top end of our 6.7% to 7.2% guidance.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 6 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. One insider sold, $114,362 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Foletta Mark GSale
15 Jun 2026, Board
- Shares
- 3,681
- Price
- $31.07
- Value
- $114,362
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at AMN Healthcare Services
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 65
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Care Facilities)
The next larger and next smaller companies by market value
- AmbeaAMBEA.ST $1.63B70
- Astrana HealthASTH $1.58B53
- U.S. Physical TherapyUSPH $1.47B55
- Aevis VictoriaAEVS.SW $1.44B34
- ClarianeCLARI.PA $1.37B39
- Innovage HoldingINNV $1.28B58
- Pennant GroupPNTG $1.26B53
- Nutex HealthNUTX $1.18B73
ETFs that hold AMN Healthcare Services
Held by 13 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Global X Telemedicine & Digital Health UCITS ETFDDOC | 1.72% | 0.68% | €5.31M |
| iShares Ageing Population UCITS ETF2B77 | 0.12% | 0.40% | €813.42M |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.09% | 0.30% | €185.82M |
Show 5 more
| iShares S&P SmallCap 600 UCITS ETFIUS3 | 0.08% | 0.30% | €2.31B |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.06% | 0.30% | €964.08M |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.05% | 0.30% | €4.28B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.05% | 0.30% | €2.22B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.04% | 0.43% | €2.5B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 8 May 2026)
- Valuation signal Fairly valued since 7 Nov 2026, previously Overvalued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.